Darbepoetin administration to neonates undergoing cooling for encephalopathy: A safety and pharmacokinetic trial

Pediatric Research

Volumn 78, Issue 3, 2015, Pages 315-322

  Baserga, Mariana C ^a   Beachy, Joanna C ^a   Roberts, Jessica K ^a   Ward, Robert M ^a   Digeronimo, Robert J ^a   Walsh, William F ^b   Ohls, Robin K ^c   Anderson, Jennifer ^c   Mayock, Dennis E ^d   Juul, Sandra E ^d   Christensen, Robert D ^e   Loertscher, Manndi C ^a   Stockmann, Chris ^a   Sherwin, Catherine M T ^a   Spigarelli, Michael G ^a   Yoder, Bradley A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e McKay Dee Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; ERYTHROPOIETIN;

ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BRAIN DISEASE; CEREBROSPINAL FLUID-TO-PLASMA RATIO; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ELIMINATION HALF-LIFE; FEEDING DIFFICULTY; FEMALE; GESTATIONAL AGE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INDUCED HYPOTHERMIA; INFANT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; LOW DRUG DOSE; LUMBAR PUNCTURE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEUTROPENIA; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYCYTHEMIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; ADOLESCENT; ADULT; BRAIN DISEASES; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; HYPOTHERMIA; MULTICENTER STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; BRAIN DISEASES; DARBEPOETIN ALFA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HUMANS; HYPOTHERMIA; HYPOTHERMIA, INDUCED; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MALE; YOUNG ADULT;

EID: 84938555566     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2015.101     Document Type: Article

References (35)

1. Graham EM, Ruis KA, Hartman AL, Northington FJ, Fox HE. A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol 2008;199:587-95
2. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2014;385:430-40
3. Shankaran S, Woldt E, Koepke T, Bedard MP, Nandyal R. Acute neonatal morbidity and long-term central nervous system sequelae of perinatal asphyxia in term infants. Early Hum Dev 1991;25:135-48
4. Robertson CM, Finer NN, Grace MG. School performance of survivors of neonatal encephalopathy associated with birth asphyxia at term. J Pediatr 1989;114:753-60
5. Shankaran S, Laptook AR, Ehrenkranz RA, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005;353:1574-84
6. Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med 2012;166:558-66
7. Cotten CM, Shankaran S. Hypothermia for hypoxic-ischemic encephalopathy. Expert Rev Obstet Gynecol 2010;5:227-39
8. Grasso G, Graziano F, Sfacteria A, et al. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery 2009;65:763-9; discussion 769-70
9. Traudt CM, McPherson RJ, Bauer LA, et al. Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 2013;35:491-503
10. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044-9
11. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 2002;99:5627-31
12. Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res 2005;58:297-301
13. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124:e218-26
14. Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010;125:e1135-42
15. Warwood TL, Ohls RK, Wiedmeier SE, et al. Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol 2005;25:725-30
16. Ohls RK, Kamath-Rayne BD, Christensen RD, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics 2014;133:1023-30
17. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-9
18. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006;18:132-8
19. Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004;505:93-101
20. Wen TC, Sadamoto Y, Tanaka J, et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 2002;67:795-803
21. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007;38:2795-803
22. Cherian L, Goodman JC, Robertson C. Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats. J Pharmacol Exp Ther 2011;337:451-6
23. Belayev L, Khoutorova L, Zhao W, et al. Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 2005;36:1071-6
24. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383-91
25. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012;130:683-91
26. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
27. Warwood TL, Ohls RK, Lambert DK, et al. Intravenous administration of darbepoetin to NICU patients. J Perinatol 2006;26:296-300
28. Widness JA, Veng-Pedersen P, Modi NB, Schmidt RL, Chestnut DH. Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J Pharmacol Exp Ther 1992;261:977-84
29. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001;298:820-4
30. Freise KJ, Widness JA, Segar JL, Schmidt RL, Veng-Pedersen P. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy. Pharm Res 2007;24:1653-9
31. STOHLMAN F Jr, BRECHER G. Humoral regulation of erythropoiesis. V. Relationship of plasma erythropoietine level to bone marrow activity. Proc Soc Exp Biol Med 1959;100:40-3
32. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74
33. Warwood TL, Ohls RK, Lambert DK, Leve EA, Veng-Pedersen P, Christensen RD. Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates. J Perinatol 2006;26:636-9
34. Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res 2007;61:671-5
35. Cheong JL, Coleman L, Hunt RW, et al.; Infant Cooling Evaluation Collaboration. Prognostic utility of magnetic resonance imaging in neonatal hypoxic-ischemic encephalopathy: substudy of a randomized trial. Arch Pediatr Adolesc Med 2012;166:634-40